Evidence map›Paper›PMID 40757924›Full record

ArticleThe oncologist2025

Real-world assessment of clinical outcomes of first-line treatment in metastatic papillary renal cell carcinoma.

Manon De Vries-Brilland, Zineb Hamilou, Sunita Ghosh, Daniel Y C Heng, Lori A Wood, Naveen S Basappa, Christian K Kollmannsberger, Jeffrey Graham, Bimal Bhindi, Antonio Finelli and 9 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The oncologist, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Manon De Vries-BrillandDepartment of Medical Oncology, Integrated Centers of Oncology (ICO) Paul Papin, Angers 49055, France.ORCID 0000-0002-9890-650X
Zineb HamilouCentre Hospitalier de l'Université de Montréal, Montreal, QC H3C 3J7, Canada.
Sunita GhoshDepartment of Oncology, University of Alberta, Edmonton, AB T6G 1Z2, Canada.
Daniel Y C HengTom Baker Cancer Centre, University of Calgary, Calgary, AB T2N 2T9, Canada.
Lori A WoodQueen Elizabeth II Health Sciences Centre, Dalhousie University, Halifax, NS B3H 2Y9, Canada.
Naveen S BasappaCross Cancer Institute, University of Alberta, Edmonton, AB T6G 1Z2, Canada.
Christian K KollmannsbergerBritish Columbia Cancer Agency, Vancouver Centre, Vancouver, BC V5Z 4E6, Canada.
Jeffrey GrahamCancerCare Manitoba, University of Manitoba, Winnipeg, MB R3E 0V9, Canada.
Bimal BhindiSouthern Alberta Institute of Urology, University of Calgary, Calgary, AB T2V 1P9, Canada.
Antonio FinelliDivision of Urology, Department of Surgery, University of Toronto, Toronto, ON M5T 1P5, Canada.
Georg A BjarnasonSunnybrook Odette Cancer Centre, University of Toronto, Toronto, ON M4N 3M5, Canada.
Dominick BosseDivision of Medical Oncology, Department of Medicine, University of Ottawa, Ottawa, ON K1H 8L6, Canada.
Frederic PouliotCHU de Quebec, Université Laval, Quebec City, QC G1R 2J6, Canada.
Vincent CastonguayHotel Dieu de Quebec, Quebec, QC G1R 2J6, Canada.
Rodney H BreauOttawa Hospital Research Institute, University of Ottawa, Ottawa, ON K1H 8L6, Canada.
Ramy R SalehDepartment of Medical Oncology, McGill University Health Centre, Montreal, QC H4A 3J1, Canada.
Eric WinquistDivision of Medical Oncology, London Health Sciences Centre & Western University, London, ON N6A 5W9, Canada.
Aly-Khan A LalaniDepartment of Medical Oncology, McMaster University, Hamilton, ON L8S 4L8Canada.
Denis SoulièresCentre Hospitalier de l'Université de Montréal, Montreal, QC H3C 3J7, Canada.

Funding

AstraZeneca
6 · The paper itself

Abstract

backgroundPapillary renal cell carcinoma (pRCC) is the most common non-clear cell RCC (nccRCC), representing up to 15% of RCC cases. Phase 2 trials have evaluated first-line (1L) immunotherapy (IO)-based treatment in nccRCC, but with heterogeneous cohorts and limited comparative data. The specific value of IO for metastatic pRCC (mpRCC) remains unquantified.

methodsWe analyzed prospectively collected data from the Canadian Kidney Cancer Information System to assess the efficacy of 1L systemic therapy in mpRCC with IO-based regimens vs tyrosine kinase inhibitors (TKI). The primary endpoint was time-to-treatment failure (TTF). Secondary endpoints included overall survival (OS), objective response rate (ORR), and treatment-related adverse events (TRAEs). Analyses were adjusted (adj) for IMDC risk groups.

resultsFrom 2011 to 2024, 197 mpRCC patients received 1L therapy: 70 with IO (alone or in combination) and 127 with TKI. Median follow-up was 21.6 months. Median TTF was 9.9 months with IO vs 5.9 months with TKI (adjHR: 0.62 [0.43-0.91], P = .01). Median OS was 36.9 months with IO vs 23.2 months with TKI (adjHR: 0.54 [0.3-0.9], P = .018). Objective response rate was 37% with IO vs 23% with TKI (adjOR: 2.2 [0.95-5.2], P = .07). The TKI-IO subgroup showed the longest TTF (16.9 months, adjHR: 0.47 [0.26-0.85], P = .01) and OS (not reached, adjHR: 0.26 [0.08-0.83], P = .02), compared to TKI. Grade 3-5 TRAEs occurred in 31% (IO) vs 27% (TKI).

conclusionsThis real-world study highlights the benefit of IO-based treatment in mpRCC, particularly in the TKI-IO subgroup. Our findings may inform further trials evaluating 1L IO in mpRCC.

Indexed as

Carcinoma, Renal CellImmunotherapyKidney NeoplasmsProtein Kinase InhibitorsAdultAgedAged, 80 and overFemaleHumansMaleMiddle AgedNeoplasm MetastasisTreatment OutcomeProtein Kinase InhibitorsCKCisfirst-line systemic treatmentimmunotherapymetastatic papillary renal-cell cancerTKI

Identifiers

PMID40757924
PMCPMC12445671

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.